| Database ID | Agent | Target | Cancer Type | Detail |
| DB00586 | figitumumab | Insulinlike growth factor I receptor | soft tissue sarcomas | view |
| DB00587 | CT322 | Vascular endothelial growth factor receptor 2 | Tumors of the nervous system | view |
| DB00588 | Vandetanib and sirolimus | NA | Tumors of the nervous system | view |
| DB00589 | bosutinib | Protooncogene tyrosineprotein kinase SRC
Abl | Tumors of the nervous system | view |
| DB00590 | PTK787/ZK 222584 | Vascular endothelial growth factor receptor 2 | Tumors of the nervous system | view |
| DB00591 | GRN1005 | lipoprotein receptorrelated protein1 | Tumors of the nervous system | view |
| DB00592 | sunitinib | FL cytokine receptor
Mast/stem cell growth factor receptor
Vascular endothelial growth factor receptor 2
Plateletderived growth factor receptor | Tumors of the nervous system | view |
| DB00593 | pazopanib and lapatinib | NA | Tumors of the nervous system | view |
| DB00594 | bevacizumab and erlotinib | NA | Tumors of the nervous system | view |
| DB00595 | bevacizumab | Vascular endothelial growth factor | Tumors of the nervous system | view |
| DB00596 | bevacizumab | Vascular endothelial growth factor | Tumors of the nervous system | view |
| DB00597 | bevacizumab | Vascular endothelial growth factor | Tumors of the nervous system | view |
| DB00598 | bevacizumab | Vascular endothelial growth factor | Tumors of the nervous system | view |
| DB00599 | bevacizumab | Vascular endothelial growth factor | Tumors of the nervous system | view |
| DB00600 | bevacizumab | Vascular endothelial growth factor | Tumors of the nervous system | view |